Tisotumab Vedotin

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Journal: Nature reviews. Clinical oncology

Published: May 18, 2026

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Journal: Gynecologic oncology

Published: February 23, 2026

Tisotumab vedotin-associated Stevens-Johnson syndrome in a patient with recurrent vulvar cancer: Vulnerability and antibody drug conjugate toxicity considerations.

Tisotumab vedotin-associated Stevens-Johnson syndrome in a patient with recurrent vulvar cancer: Vulnerability and antibody drug conjugate toxicity considerations.

Journal: Gynecologic oncology reports

Published: February 13, 2026

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Journal: Gynecologic oncology

Published: February 02, 2026

Molecular Targets of Cervical Cancer and Its Microenvironment: Advances in Treatment.

Molecular Targets of Cervical Cancer and Its Microenvironment: Advances in Treatment.

Journal: Cancers

Published: December 30, 2025

Latest Drug Therapies for Cervical Cancer

Latest Drug Therapies for Cervical Cancer

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: December 24, 2025

Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer.

Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: December 12, 2025

Advances in Screening, Immunotherapy, Targeted Agents, and Precision Surgery in Cervical Cancer: A Comprehensive Clinical Review (2018-2025).

Advances in Screening, Immunotherapy, Targeted Agents, and Precision Surgery in Cervical Cancer: A Comprehensive Clinical Review (2018-2025).

Journal: Current oncology (Toronto, Ont.)

Published: November 23, 2025

New developments in the treatment of cervical cancer in 2026.

New developments in the treatment of cervical cancer in 2026.

Journal: Current opinion in obstetrics & gynecology

Published: November 17, 2025

Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.

Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: November 03, 2025

Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application.

Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application.

Journal: Hematology/oncology clinics of North America

Published: October 31, 2025

Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Journal: Chinese medical journal

Published: September 22, 2025

Showing 1-12 of 110

Last Updated: 06/30/2026